Aldeyra Therapeutics receives fast track designation for ADX-2191 for prevention of proliferative vitreoretinopathy

This article was originally published here

“Fast track designation is an important milestone for our retinal disease platform, and promising news for PVR patients,” said Todd C. Brady, M.D., Ph.D., President and Chief Executive

The post Aldeyra Therapeutics receives fast track designation for ADX-2191 for prevention of proliferative vitreoretinopathy appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply